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AbstrAct
primary MaLt lymphoma arising at the dura is a rare circumstance with no categorical therapeutic plan in literature. there are 
few reports available with different treatment courses. Here, we report two cases with a long-term follow-up after the same 
pattern of management and review the literature. 
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Introduction
Marginal zone B-cell lymphomas (MZBCL) are 
responsible for 7–8% of all B-cell lymphomas, with 
a median age of 60 years at diagnosis. Marginal 
zone B-cell lymphomas, first described as a distinct 
low-grade lymphoma of mucosa-associated lym-
phoid tissue (MALT), is frequently associated with 
the gastric mucosa (30% of all MALT lymphomas) 
[1]. Other possible sites widely described in litera-
ture are head and neck (30%), ocular adnexa (24%), 
lungs (12%), skin (12%), thyroid (7%) and breasts 
(2%) [2].
MALT lymphomas usually present themselves 
with indolent course and etiology related to lym-
phoid proliferation due to immune chronic stimu-
lation by infectious agents (ex. Helicobacter Pylori, 
Campylobacter Jejiuni) or autoimmune diseases 
(such as Hashimoto tireoiditis, Crohn’s disease) [3].
There are few publications about MALT lym-
phomas of the dura with nearly 100 reported cases 
in the literature[4]. The lack of prospective studies 
reflects the inconsistency in therapeutic approach, 
even among patients treated at the same institu-
tion. In this manuscript, we report two patients 
diagnosed with MALT lymphoma of the dura, both 
receiving the same treatment at our department 
and with a long follow-up time (6 and 8 years).
case reports
case 1
A 59-year-old woman presented a history of 
one episode of seizure in August, 2010. She denied 
previous episodes and after screening the central 
nervous system (CNS) a lesion was observed in cra-
nial magnetic resonance imaging (MRI). The lesion 
was characterized as an extra-dural and subdural 
expansive formation with diffuse post contrast en-
hancement of approximately 1.5 cm in diameter 
with vasogenic edema of the adjacent parenchyma. 
A craniotomy was performed with total resection 
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of the lesion. Microscopic examination of the le-
sion showed diffuse dural infiltration by small mo-
notonous lymphocytes, with some regressive and 
colonized lymphoid follicles. Immunohistochem-
istry demonstrated positivity for CD20 and Bcl-2, 
with residual meshwork of follicular dendritic cells 
highlighted by CD23 and a low proliferative index, 
consistent with the diagnosis of an extranodal mar-
ginal zone lymphoma (Fig. 1). The patient was then 
referred to our institution where it was decided 
to deliver adjuvant conformal radiotherapy with 
a dose of 21 Gy in 14 fractions to the whole brain 
and a boost of 9 Gy in 6 fractions to the tumor bed, 
completing a total dose of 30 Gy delivered in 20 
fractions of 1.5 Gy (Fig. 2). Patient kept follow-up 
visits every 6 months with cranial MRI during the 
first year and annually after that, with no evidence 
of disease recurrence after a follow-up time of 7 
years (Fig. 3). After 8 years and 4 months, she had 
no clinical complaints nor signs of cognitive im-
pairment. 
case 2
A 62-year-old woman started with seizures in De-
cember 2011 and afterwards in September 2012. At 
the investigation, a cranial MRI showed extra-axial 
lesions compromising the pachymeningeal coating 
of a great part of the left cerebral hemisphere, with 
approximately 2.5 cm at the maximum width. They 
were initially suspected to be meningioma based 
on the MRI and a subtotal resection of the lesions 
was performed in December, 2012. She was then 
referred to our department. The histopathological 
analysis of the lesions described similar features as 
Figure 2. treatment planning with 3D technique and dose 
distribution between 2100 and 3218.4 cGy
Figure 3. rM of the brain after 5 years of irradiation 
exhibiting good local control of the disease and no sign 
of recurrence
Figure 1. A. Duramater was diffusely infiltrated by sheets of small neoplastic lymphocytes (H&e, 100×). b. remnants of 
colonizes lymphoid follicles could be seen (H&e, 200×). c. Most of the cells had clear cytoplasm, giving a monocytoid 
appearance (H&e, 400×). D. those cells showed strong and diffuse cD20 staining (cD20, 200×). E. cD21 antibody highlighted 
the residual meshwork of follicular dendritic cells (cD21, 200×). F. the proliferating index was low, with weak staining in less 
than 5% of the cells (Ki-67, 400×)
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those in case one, consistent with marginal zone 
B-cell lymphoma/MALT. Post-operative cranial 
MRI revealed significant residual disease. It was 
decided to deliver adjuvant intensity-modulated 
radiotherapy (IMRT with a dose of 21 Gy in 14 
fractions to the whole brain and a boost of 9 Gy in 6 
fractions to the tumor bed, completing a total dose 
of 30 Gy delivered in 20 fractions of 1.5 Gy (Fig. 4). 
Patient kept follow-up visits every 6 months with 
cranial MRI during the first year and annually after 
that. A complete response was achieved with no 
signs of disease recurrence, after a follow-up time of 
6 years and 9 months (Fig. 5). She also had no clini-
cal complaints nor signs of cognitive impairment at 
the last follow-up visit.
Discussion
Primary central nervous system lymphoma 
(PCNSL) is a non-Hodgkin extranodal lympho-
ma of the brain, neuro-ocular structures, or spinal 
cord. Although infiltration into adjacent meninges 
is occasionally seen, exclusively meningeal involve-
ment is extremely rare. Treatment is based on radio-
therapy and intrathecal chemotherapy, frequently 
involving severe neurotoxicity [5]. Nevertheless, 
although 90% of PCNSLs are diffuse large B-cell 
lymphomas with poor prognosis, there are indo-
lent histological variations with a more favourable 
clinical course; therefore, accurate recognition of 
these rare subtypes is of utmost importance. One of 
these subtypes is lymphoma of mucosa-associated 
lymphoid tissue (MALT).
When occurring in the CNS, MALT lymphomas 
generally arise at the dura, in contrast to other his-
tological subtypes that present themselves mainly 
at the brain parenchyma. It is a rare condition, 
with no prospective studies and with few published 
case reports with heterogeneous therapeutic ap-
proaches.
There is still no clear explanation for its patho-
genesis. One of the most plausible hypotheses is that 
a sub-clinic inflammation of the dura could recruit 
lymphocytes to the region from which a mono-
clonal expansion could originate and, eventually, 
lymphoma arises. Regarding the role of infectious 
agents in the development of the disease, none were 
identified [2]. Due to a strong predominance in the 
female population, one could hypothesize a hor-
monal role in its pathophysiology [8].
Initially reported by Kumar et al. [6] in 1997, 15 
years after the first MALT lymphomas description, 
there are nearly 100 reported cases in literature 
of MALT arising at the dura[4]. Appearing more 
frequently in the fourth and fifth decades (sooner 
than most indolent lymphoproliferative neoplasms) 
[7], with a male to female ratio of 1:5, it is usually 
characterized as a slowly growing dural mass with 
no infiltrative aspect or systemic involvement. The 
most frequent symptoms are headaches, dizziness, 
nausea, vomitting and a slow and progressive mem-
ory impairment [9].
Figure 4. treatment planning with IMrt technique 
and dose distribution between 2100 and 3245.6 cGy
Figure 5. rM of the brain after 3 years of irradiation with 
good local control of the disease and no sign of recurrence
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At CT/MRI scans, MALT lymphomas bear a dis-
tinct resemblance to meningiomas, therefore being 
usually misdiagnosed at first. It presents itself as an 
extra axial, solid lesion, frequently exhibiting a sign 
known as “dura tail”, which is a contrast enhancing, 
filiform prolongation of the dura, suggestive but not 
specific of meningiomas in MRIs. Furthermore, the 
typical MRI signal intensity characteristics consist 
of isointensity to slight hypointensity relative to grey 
matter on the T1-weighted sequence and isointen-
sity to slight hypointensity relative to grey matter 
on the T2 sequence. Beside that, it demonstrates 
homogeneous and intense contrast enhancement.
Due to its rarity, there is scarce evidence to guide 
medical decision. In MALT lymphomas of other 
sites (not associated with infectious causes), treat-
ment involving radiotherapy or surgical resection 
offers good results [9]. In a systematic review by 
Beltran et al. [8] that included 91 patients with 
primary MALT lymphomas of the dura, 70% re-
ceived surgical treatment, 73% radiotherapy and 
37% chemotherapy. Chemotherapy included intra-
thecal methotrexate, CHOP scheme, among others. 
Because the role of chemotherapy is not entirely 
clear and commonly associated with severe toxicity, 
there is a chance that we may be overtreating some 
patients. Radiotherapy is not considered a standard 
treatment in patients with this tumor. The radiation 
volume varied between whole brain radiotherapy 
(WBRT), involved field radiotherapy and a combi-
nation of both. When combined, the mean whole 
brain dose was 36 Gy (21–40 Gy) with boost up to 
50 Gy (36–60 Gy) in involved fields. 
The recent International Lymphoma Radiation 
Oncology Group (ILROG) guideline suggests that 
if more than 1 lesion is present, whole brain to 24 
Gy and boosting the involved sites with additional 
12 Gy should be indicated. A single lesion may be 
treated with the presurgical/biopsy MRI volume to 
the gross tumor Volume plus margins constitut-
ing the clinical target volume to 30 to 36 Gy [11]. 
Suchrecommendation is quite similar to our ap-
proach, justified by the diffuse dural involvement.
In the largest published series on dural lympho-
ma, with 26 patients treated at the Memorial Sloan 
Kettering Cancer Center and University of Miami, 
17 patients underwent resection and 9 had a bi-
opsy. From the patients who received radiotherapy, 
13 received focal intensity-modulated radiotherapy 
(16 to 36 Gy in 9 to 20 fractions) and 6 WBRT 
(36 to 39 Gy in 20 to 26 fractions), 3 of whom had 
multifocal disease. One patient received chemo-
therapy followed by WBRT (45 Gy in 25 fractions). 
Only 4 patients relapsed (2 local and 2 systemic) 
after a median follow-up of 64 months. The 3-year 
progression free survival was 89% and all patients 
were alive at last follow-up.[12].
Bustoros et al. [4] reviewed 104 patients in a lit-
erature search. Most of them (64%) were treated 
with two modalities including resection, RT or 
chemotherapy, and the majority achieved complete 
remission on follow-up (only 12 relapses). These 
data confirmed the favorable prognosis of dural 
lymphomas and showed a high salvage rate in the 
case of relapse.
Based on the few case reports available, with lim-
ited follow-up time, and the radiosensitivity of this 
histological subtype, we believe that surgical treat-
ment, especially in cases with mass effect symp-
toms, followed by radiotherapy alone may offer 
adequate disease control. Both reported cases were 
treated with this rationale, achieving satisfactory 
oncologic and toxicity outcomes after a long-term 
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